基于肽核酸预靶向策略的161Tb放射核素治疗在小鼠肿瘤模型中的验证
本研究在4T1荷瘤小鼠模型中验证肽核酸(PNA)介导的预靶向161Tb放射核素治疗能否减缓肿瘤生长并降低全身辐射暴露。结果显示预靶向组血液放射性分布较常规组低32倍(0.37 ± 0.05%ID/g vs. 11.93 ± 0.62%ID/g,P < 0.05),但常规治疗组抑瘤效果优于预靶向组,预靶向组又优于对照组(345.09 ± 4.93 vs. 100.76 ± 12.20 vs. 183.02 ± 12.94 mm3,P < 0.05)。
要点
- 预靶向组血液放射性分布较常规组降低32倍,显著减少全身辐射暴露。
- 常规治疗组抑瘤效果优于预靶向组,预靶向组优于对照组。
- 治疗组重要器官未见明显病理改变,离体肿瘤分析支持治疗趋势。
核心结论
- 与常规非预靶向放射核素治疗相比,基于PNA的预靶向161Tb治疗降低了全身辐射暴露、显著减少血液毒性并抑制荷瘤小鼠肿瘤生长。
研究设计与样本
- 在4T1荷瘤小鼠模型中比较常规161Tb-EB-RGD与预靶向161Tb-cPNA-PNA-EB-RGD的放射核素治疗效果。
主要发现
- 68Ga-EB-RGD、68Ga-cPNA-PNA-EB-RGD、161Tb-EB-RGD和161Tb-cPNA-PNA-EB-RGD标记效率均超过80%且在磷酸盐缓冲液中高度稳定。
- 161Tb-EB-RGD与161Tb-cPNA-PNA-EB-RGD的肿瘤细胞摄取和凋亡诱导相当(0.95倍)。
- 预靶向受体PNA-EB-RGD与配体cPNA的结合能力达到80%。
- 预靶向组血液放射性分布为0.37 ± 0.05%ID/g,常规组为11.93 ± 0.62%ID/g,预靶向组低32倍(P < 0.05)。
- 161Tb-EB-RGD与161Tb-cPNA-PNA-EB-RGD在4T1肿瘤细胞中的分布分别为8.77 ± 0.16%ID/g和3.86 ± 0.21%ID/g。
关键数值与推荐
- 常规治疗组、预靶向组和对照组的肿瘤体积分别为345.09 ± 4.93、100.76 ± 12.20和183.02 ± 12.94 mm3(P < 0.05)。
临床怎么用
- 预靶向策略可降低血液放射性分布和全身辐射暴露,但本模型中抑瘤效果不及常规治疗,需进一步优化以实现疗效与安全性的平衡。
局限性
- 研究仅在小鼠4T1肿瘤模型中进行,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although molecular tumor-targeting peptides modified with albumin-binding domains can enhance tumor probe uptake and prolong tumor retention time, the prolonged systemic circulation resulting from this modification also increases radiation exposure to normal tissues. This study aims to validate that peptide nucleic acid (PNA)-mediated pretargeted 161Tb radionuclide therapy can slow tumor growth and reduce systemic radiation exposure. RESULTS: 68Ga-EB-RGD, 68Ga-cPNA-PNA-EB-RGD, 161Tb-EB-RGD, and 161Tb-cPNA-PNA-EB-RGD all demonstrated labeling efficiencies exceeding 80% and exhibited high stability in phosphate-buffered saline. 161Tb-EB-RGD and 161Tb-cPNA-PNA-EB-RGD showed comparable tumor cell uptake and apoptosis induction (0.95-fold). The binding capability between the pretargeting receptor PNA-EB-RGD and the ligand cPNA reached 80%. The blood biodistribution of the pretargeting group (161Tb-cPNA-PNA-EB-RGD) was 32-fold lower than that of the conventional group (161Tb-EB-RGD) (0.37 ± 0.05%ID/g vs. 11.93 ± 0.62%ID/g, P < 0.05). The biodistribution of 161Tb-EB-RGD and 161Tb-cPNA-PNA-EB-RGD in 4T1 tumor cells was 8.77 ± 0.16%ID/g and 3.86 ± 0.21%ID/g, respectively. The conventional treatment group (161Tb-EB-RGD) showed superior therapeutic efficacy compared to the pretargeting group (161Tb-cPNA-PNA-EB-RGD), which in turn outperformed the control group (345.09 ± 4.93 vs. 100.76 ± 12.20 vs. 183.02 ± 12.94 mm3, P < 0.05). No significant pathological changes were detected in the vital organs of treated animals. Ex vivo tumor analysis supported the treatment trends. CONCLUSIONS: Compared to conventional non-pretargeted radionuclide therapy, PNA-based pretargeted 161Tb radionuclide therapy reduced systemic radiation exposure, significantly decreased hematotoxicity, and suppressed tumor growth in tumor-bearing mice.
引用
- Li H, Xiang X, Guan L, et al. A peptide nucleic acid-based pretargeting approach using 161Tb for radionuclide therapy in a murine tumor model. EJNMMI Res. 2026. PMID: 41615531. doi:10.1186/s13550-026-01382-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。